What is Acute Coronary Syndrome Treatment Market?
Acute Coronary Syndrome is an umbrella term that refers to a spectrum of conditions compatible with acute myocardial ischemia and/or infarction that are usually due to an abrupt reduction in coronary blood flow.
The traditional types of Acute Coronary Syndrome comprise of
myocardial infarction with ST-segment elevation (STEMI), which generally
reflects an acute total coronary occlusion, myocardial infarction without
ST-segment elevation (NSTEMI), and unstable angina (UA), with or without
myocardial injury, respectively.
DelveInsight's Acute
Coronary Syndrome Market Insights, Epidemiology, and Market
Forecast-2030 report delivers an in-depth understanding of the Acute
Coronary Syndrome, historical and forecasted epidemiology as well as the Acute
Coronary Syndrome market trends in the United States, EU5 (Germany, Spain,
Italy, France, and United Kingdom) and Japan.
Some facts of Acute
Coronary Syndrome Market are:
·
As per
the results of Newmann et al. (2020), between 2005 and 2015, a total of
3797,546 cases of Acute Coronary Syndrome were recorded. The mean age was 69
years and 36% were females. From 2005 to 2015, the incidence rates of ACS,
ST-elevation MI, and unstable angina pectoris decreased, while the incidence
rate of non-ST-elevation MI increased. The percentages of performed coronary
angiographies and percutaneous coronary interventions increased from 52% to 70%
and 34 to 50%, respectively.
·
According
to a study conducted in Japan by Daida et al. (2013), ST-segment elevation
myocardial infarction (STEMI) was the most frequent type of Acute Coronary
Syndrome (59.4%). The vast majority (93.5%) of patients underwent percutaneous
coronary intervention (PCI), with a success rate of 93.9%.
·
According
to available literature, males are affected more as compared to females, in the
case of ACS.
·
Gayle et
al. (2017) stated that in 2014/15, there were 83,842 admissions to National
Health Service hospitals in England and Wales, Northern Ireland, and Isle of
Man with AMI as recorded in the UK national registry, Myocardial Ischaemia
National Audit Project (MINAP). Of these, STEMI and NSTEMI comprised 40.5% and
59.5%, respectively. The ratio of STEMI to NSTEMI hospitalizations as recorded
in MINAP has not changed over the last five years, from 1:1.50 in 2009/10 to
1:1.47 in 2014/15.
View Report: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
Download Sample Report here: https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market
Scope of Acute
Coronary Syndrome Market are
·
The
report covers the descriptive overview of Acute Coronary Syndrome, explaining
its causes, signs and symptoms, pathophysiology, diagnosis and currently
available therapies
·
Comprehensive
insight has been provided into the Acute Coronary Syndrome epidemiology and
treatment in the 7MM
·
Additionally,
an all-inclusive account of both the current and emerging therapies for Acute
Coronary Syndrome are provided, along with the assessment of new therapies,
which will have an impact on the current treatment landscape
·
A
detailed review of Acute Coronary Syndrome market; historical and forecasted is
included in the report, covering drug outreach in the 7MM
·
The
report provides an edge while developing business strategies, by understanding
trends shaping and driving the global Acute Coronary Syndrome market
View Report: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
Request for Sample Report here: https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market
Some of Acute
Coronary Syndrome Companies are:
·
Regeneron
·
Sanofi
·
DalCor
Pharmaceutical
·
CSL
Behring
·
AStraZeneca
·
And Many
Others
View Report: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
Request for Free Sample Report here: https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market
Acute
Coronary Syndrome Therapies are:
·
Alirocumab
·
Dalcetrapib
·
CSL112
·
Brilinta
·
And Many
Others
Table of Contents:
1. Key Insights
2. Executive Summary
of Acute Coronary Syndrome
3. Competitive
Intelligence Analysis for Acute Coronary Syndrome
4. Acute Coronary
Syndrome: Market Overview at a Glance
4.1. Acute Coronary Syndrome Total Market Share (%)
Distribution in 2018
4.2. Acute Coronary Syndrome Total Market Share (%)
Distribution in 2030
5. Acute Coronary
Syndrome: Disease Background and Overview
6. Patient Journey
7. Acute Coronary
Syndrome Epidemiology and Patient Population
8. Treatment
Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of
Acute Coronary Syndrome Treatment
11. Marketed
Products
List to be continued in report
12. Emerging
Therapies
List to be continued in report
13. Acute Coronary
Syndrome: Seven Major Market Analysis
14. Attribute
analysis
15. 7MM: Market
Outlook
16. Access and
Reimbursement Overview of Acute Coronary Syndrome
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight
Capabilities
22. Disclaimer
Related Reports:
·
Acute
Agitation And Aggression Market
·
Diagnostic
Imaging Equipment Market
About Delveinsight:
DelveInsight Business Research is a leading Market
Research, and Business Consultant focused purely on Healthcare. It
helps pharma companies by providing them with end-to-end services to solve
their business problems.
Know More about our competitive
intelligence services.
Get hold of all the Pharma and healthcare market research
reports on our market research subscription-based platform PharmDelve.
Media Contact
Company Name: DelveInsight Business
Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Comments
Post a Comment